European Pharmaceutical Review – VOLUME 21 ISSUE 3 2016
“Understanding the financial implications of the upcoming falsified medicines regulations” – Maarten Van Baelen and Johan Verhaeghe
El presidente de la EGA considera que actualmente la industria europea de genéricos está “atada de manos”.
After a long dry spell, the pharmaceutical research industry has brought to market a spate of innovative treatments that can extend life and often have fewer side effects than older treatments. But these medicines are not affordable to most of the people who need them. Recent treatments for hepatitis C and cancer – both widespread conditions globally – can cost from $50,000 annually to well over $150,000.